Dyadic International, Inc. Announces Research and Development Collaboration with Mitsubishi Tanabe Pharma Corporation To Prod...
February 27 2018 - 8:30AM
JUPITER, Fla., Feb. 27, 2018 (GLOBE NEWSWIRE) --
Dyadic International, Inc. (“Dyadic”) (OTCQX:DYAI), a global
biotechnology company focused on further improving and applying its
proprietary C1 gene expression platform to speed up the development
and production of biologic products at commercial scales, today
announced that it has entered into a funded proof of concept
research collaboration to explore the potential of its C1
technology to produce two vital therapeutic proteins for human
health indications with Mitsubishi Tanabe Pharma Corp., one of the
World’s top tier pharmaceutical companies.
“We are very pleased to have the
opportunity to collaborate with Mitsubishi Tanabe Pharma Corp. to
express two of its important therapeutic compounds using our C1
production platform”, said Mark Emalfarb, Dyadic’s CEO. “This
research and development program is aiming to help Mitsubishi
Tanabe overcome specific gene expression challenges and to further
demonstrate the potential of C1 to become a platform of choice for
manufacturing protein-based biologics because of its speed of
development and low cost of goods.”
“In this research collaboration, we will be
using our proprietary synthetic biology and genome engineering
techniques to further modify our C1 host production organism to
produce the desired therapeutic proteins”, said Ronen Tchelet,
Ph.D., Dyadic’s Head of Research. “We have already proved
that our C1 technology is capable of speeding up the development
process and producing certain monoclonal antibodies (mAbs) at
commercially important levels. We expect this project to generate
additional data and to enlarge the diversity of the types of
proteins that our C1 platform can potentially produce at higher
yields and with lower cost.”
About Dyadic International,
Inc.
Dyadic International, Inc. is a global
biotechnology company which is developing what it believes will be
a potentially significant biopharmaceutical gene expression
platform based on the fungus Myceliophthora thermophila,
nicknamed C1. The C1 microorganism, which enables the development
and large-scale manufacture of low cost proteins, has the potential
to be further developed into a safe and efficient expression system
that may help speed up the development, lower production costs and
improve the performance of biologic vaccines and drugs at flexible
commercial scales. Dyadic is using the C1 technology and
other technologies to conduct research, development and commercial
activities for the development and manufacturing of human and
animal vaccines, monoclonal antibodies, biosimilars and/or
biobetters, and other therapeutic proteins. Additionally, the
Company has entered into a proof of concept research project to
explore the potential of its C1 technology to produce an important
active moiety for a third party. Dyadic pursues research and
development collaborations, licensing arrangements and other
commercial opportunities with its partners and collaborators to
leverage the value and benefits of using these technologies in the
development and manufacture of biopharmaceuticals. In particular,
as the aging population grows in developed and undeveloped
countries, Dyadic believes the C1 technology may help bring
biologic vaccines & drugs to market faster, in greater volumes,
at lower cost, and potentially with new properties to drug
developers and manufacturers and, hopefully, improve access and
cost to patients and the healthcare system, but most importantly
save lives.
Please visit Dyadic’s website at www.dyadic.com
for additional information, including details regarding Dyadic’s
plans for its biopharmaceutical business.
Dyadic trades on the OTCQX tier of the OTC
marketplace. Investors can find real-time quotes, market
information and financial reports for Dyadic in the Company’s
annual and quarterly reports which are filed with the OTC markets.
Please visit the OTC markets website at
www.otcmarkets.com/stock/DYAI/quote.
Safe Harbor Regarding Forward-Looking
Statements
Certain statements contained in this press
release are forward-looking statements within the meaning of the
federal securities laws. These forward-looking statements involve
risks, uncertainties and other factors that could cause Dyadic’s
actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Investors
are urged to consider these factors carefully in evaluating the
forward-looking statements and are cautioned not to place undue
reliance on such forward-looking statements. Any forward-looking
statements speak only as of the date of this press release and,
except as required by law, Dyadic expressly disclaims any intent or
obligation to update or revise any forward-looking statements to
reflect actual results, any changes in expectations or any change
in events. Factors that could cause results to differ materially
include, but are not limited to: (1) general economic, political
and market conditions; (2) our ability to carry out and implement
our biopharmaceutical research and business plans and strategic
initiatives; (3) Dyadic’s ability to retain and attract employees,
consultants, directors and advisors; (4) our ability to implement
and successfully carry out Dyadic’s and third parties research and
development efforts; (5) our ability to obtain new license and
research agreements; (6) our ability to maintain our existing
access to, and/or expand access to third party contract research
organizations in order to carry out our research projects for
ourselves and third parties; (7) competitive pressures and reliance
on key third-party and related party research organizations,
customers and collaborators; and (8) other factors discussed in
Dyadic’s publicly available filings, including information set
forth under the caption “Risk Factors” in our December 31, 2016,
Annual Report filed with OTC Markets on March 24, 2017. New risks
and uncertainties arise from time to time, and it is impossible for
us to predict these events or how they may affect us.
Contact:
Dyadic International, Inc.
Thomas L. Dubinski
Chief Financial Officer
Phone: 561-743-8333
Email: tdubinski@dyadic.com
Dyadic (NASDAQ:DYAI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Dyadic (NASDAQ:DYAI)
Historical Stock Chart
From Sep 2023 to Sep 2024